Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0794
    -0.0035 (-0.32%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2624
    -0.0014 (-0.11%)
     
  • USD/JPY

    151.4160
    +0.1700 (+0.11%)
     
  • Bitcoin USD

    70,831.45
    +1,446.73 (+2.09%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Adamas (ADMS) Surges on Positive Data on Lead Candidate

Adamas Pharmaceuticals, Inc. ADMS skyrocketed a phenomenal 83% on Dec 23 on positive data from the phase III EASE LID study on its lead wholly-owned candidate ADS-5102 extended-release capsules, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease.

In the multi-center, randomized, double-blind, placebo-controlled phase III EASE LID study, a statistically significant reduction (23%) in LID at 12 weeks was observed in patients who received ADS-5102 as compared to placebo, as assessed by the Unified Dyskinesia Rating Scale (UDysRS). The study duly met its primary endpoint. The LID reduction was maintained at 24 weeks. Additionally, there were four additional key secondary analyses based on patient diary data, all of which achieved statistical significance.

We believe, encouraging data from the phase III EASE LID study will enable the company to submit regulatory application to the FDA for ADS-5102.

According to Adamas Pharma, no drug has yet been approved in the U.S. or Europe for the treatment of levodopa-induced dyskinesia. In this scenario, ADS-5102 has the opportunity to grab a good share of the market, if successfully developed and commercialized.

Apart from the EASE LID study, the company is presently conducting EASE LID 3 (phase III study to assess the efficacy of a 340 mg dose of ADS-5102 administered once daily at bedtime; enrollment completed in Dec 2015) and EASE LID 2 (an open-label safety study, which is open to patients from EASED, EASE LID, EASE LID 3 and LID patients who have undergone deep brain stimulation).

Adamas Pharma currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Achillion Pharmaceuticals, Inc. ACHN, Horizon Pharma plc HZNP and Corcept Therapeutics Incorporated CORT. All the three stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
HORIZON PHARMA (HZNP): Free Stock Analysis Report
 
CORCEPT THERAPT (CORT): Free Stock Analysis Report
 
ACHILLION PHARM (ACHN): Free Stock Analysis Report
 
ADAMAS PHARMA (ADMS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement